Implantica Sets Stockholm Capital Markets Day Following FDA Approval

The event, scheduled for 14:00 to 16:30 CEST at Sergelkonferensen on Mäster Samuelsgatan 42, marks a pivot point for the Liechtenstein-based company. CEO and founder Peter Forsell described the upcoming session as a defining moment, aiming to provide a granular look at the commercial roadmap for RefluxStop, an implantable device designed to treat gastroesophageal reflux disease without the side effects associated with traditional surgical wrapping techniques.

Beyond corporate strategy, the afternoon session will feature perspectives from both surgeons and patients familiar with the technology. Implantica, which is listed on the Nasdaq First North Premier Growth Market, intends to use the platform to demonstrate how its device addresses the root cause of acid reflux while maintaining natural esophageal function. Interested parties are required to register for the presentation via email, with further agenda details expected closer to the September 9 date.